|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.001500 EUR | -.--% |
|
-.--% | -25.00% |
| 23/07 | WINNERS & LOSERS: capAI gains exclusive licence for Ageotype platform | AN |
| 21/07 | WINNERS & LOSERS: Harvest Minerals surges on Brazil portfolio takeover | AN |
| Market Cap | 37.84L 50.94L 44.28L 41.22L 71.46L 49Cr 72.57L 4.86Cr 1.91Cr 24Cr 1.91Cr 1.87Cr 81Cr | P/E 2024 |
-0.13x | P/E 2025 | -5.88x |
|---|---|---|---|---|---|
| Enterprise Value | 36.87L 49.63L 43.14L 40.15L 69.62L 47Cr 70.7L 4.73Cr 1.86Cr 24Cr 1.86Cr 1.82Cr 79Cr | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
94.63% | Yield 2024 * |
-
| Yield 2025 | - |
| 23/25/23 | Nuformix : Prospectus | PU |
| 05/23/05 | Nuformix to fund its unlicensed programs with NXP001 windfall | AQ |
| 20/22/20 | Nuformix hoping to "initiate discussions with major pharma" in 2023 | AQ |
| 20/22/20 | Nuformix hoping to 'initiate discussions with major pharma' in 2023 | EQ |
| 18/20/18 | Nuformix : Appointment of Dr Karl Keegan | PU |
| 1 month | +200.00% | ||
| 3 months | +200.00% | ||
| 6 months | +50.00% | ||
| Current year | -25.00% |
| 1 week | 0 |  | 0 |
| 1 month | 0 | | 0 |
| 3 years | 0 | | 0 |
| 5 years | 0 | | 0.02 |
| Manager | Title | Age | Since |
|---|---|---|---|
Shaun Zulafqar
SEC | Corporate Secretary | - | 29/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Daniel Gooding
CHM | Chairman | 53 | 05/02/2020 |
Julian Gilbert
CHM | Chairman | 65 | 28/07/2022 |
| Director/Board Member | 61 | 02/12/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | +200.00% | -25.00% | 50.94L | |
| -0.53% | -3.95% | +55.23% | +152.74% | 1,02400Cr | |
| +0.21% | -2.68% | +55.61% | +53.02% | 62TCr | |
| -2.51% | -3.25% | +32.76% | +67.76% | 44TCr | |
| +0.06% | -0.42% | +37.53% | +30.67% | 35TCr | |
| -0.14% | -0.24% | +34.41% | +39.01% | 30TCr | |
| -0.69% | -0.30% | +11.55% | +12.93% | 26TCr | |
| -7.37% | -4.40% | -2.54% | -43.87% | 21TCr | |
| -0.64% | +2.43% | +30.52% | +64.49% | 21TCr | |
| -0.82% | +0.70% | +15.96% | +71.01% | 16TCr | |
| Average | -1.38% | -1.20% | +47.10% | +42.28% | 39.71TCr | |
| Weighted average by Cap. | -0.99% | -1.93% | +39.24% | +72.95% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -36.41L -49.02L -42.61L -39.66L -68.77L -47Cr -69.83L -4.68Cr -1.83Cr -23Cr -1.84Cr -1.8Cr -78Cr | -7L -9L -8L -7L -12.32L -8.39Cr -12.51L -83.78L -32.88L -4.17Cr -32.99L -32.27L -14Cr |
| Net Debt | -20.21T -27.2T -23.65T -22.01T -38.16T -25.97L -38.76T -3L -1L -12.93L -1L -99.93T -43.35L | -97.55T -1L -1L -1L -2L -1.25Cr -2L -12.52L -5L -62.41L -5L -5L -2.09Cr |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change |
|---|---|---|
| 31/26/31 | €0.001500 | -.--% |
| 30/26/30 | €0.001500 | -.--% |
| 29/26/29 | €0.001500 | -.--% |
| 28/26/28 | €0.001500 | -.--% |
| 27/26/27 | €0.001500 | -.--% |
- Stock Market
- Stocks
- LVRT Stock
- 1RT Stock
Select your edition
All financial news and data tailored to specific country editions
